GPCR — Structure Therapeutics Share News
0.000.00%
Last trade - 00:00Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
Eli Lilly rises after US FDA approves weight-loss pill
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia
U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp
Structure rises after obesity pill shows up to 16.3% weight loss in study
U.S. STOCKS ON THE MOVE-Intuit, Acumen, Circle,
Brief: Structure Therapeutics Reports Positive Topline Data From Phase 2 Access Ii Trial With Once-Daily Oral Small Molecule Glp-1 Receptor Agonist, Aleniglipron
Structure rises after obesity pill shows up to 16.3% weight loss in study
Structure's obesity pill shows up to 16.3% weight loss in study (updated)
Structure's obesity pill shows up to 16.3% weight loss in study
Factbox: Top pharma companies racing to launch a weight-loss pill
Structure Therapeutics swings to profit in Q4
Brief: Structure Therapeutics Inc. FY Net Income USD -141.202 Million
Novo Nordisk, obesity firms drop on report of Hims Wegovy pill copy launch
Novo Nordisk, obesity firms drop on report of Hims Wegovy pill copy launch
Newscasts - Wall Street ends sharply down as traders fret about AI disruption
Obesity stocks slump on Novo's underwhelming 2026 sales forecast (updated)